Abstract CT082: Capmatinib in <i>MET</i>ex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY <i>mono-1</i> study, including efficacy in patients (pts) with brain metastases (BM)

Authors: Edward B. Garon, Rebecca S. Heist, Takashi Seto, Ji-Youn Han, Noemi Reguart, Harry J. Groen, Daniel SW Tan, Toyoaki Hida, Maja J. de Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Monica Giovannini, Juergen Wolf

Published: 2020-09-04

DOI: 10.1158/1538-7445.am2020-ct082

Source: Full article